Company news

Absci Corporation news in 2024

Absci Corporation's news releases, calls and decks from 2024, newest first.

View company

Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day

December 11, 2024

Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference

November 20, 2024

Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results

November 11, 2024

Absci to Host R&D Day on December 12, 2024

November 6, 2024

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

October 30, 2024

Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024

October 14, 2024

Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results

August 13, 2024

Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI

August 11, 2024

Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024

July 9, 2024

Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit

June 11, 2024

Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 27, 2024

Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results

May 13, 2024

Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024

April 15, 2024

Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 27, 2024

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

March 20, 2024

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

February 29, 2024

Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

February 20, 2024

Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

January 9, 2024

Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

January 7, 2024

Absci to Participate in the 26th Annual Needham Growth Conference

January 2, 2024

Calls in 2024

Decks in 2024